News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
794,243 Results
Type
Article (74308)
Company Profile (620)
Press Release (719315)
Section
Business (226634)
Career Advice (3716)
Deals (39125)
Drug Delivery (102)
Drug Development (88620)
Employer Resources (192)
FDA (17549)
Job Trends (17012)
News (385578)
Policy (38635)
Tag
Academia (2968)
Africa (1187)
Alabama (33)
Allergies (41)
Alliances (55577)
Alzheimer's disease (1192)
Antibody-drug conjugate (ADC) (59)
Approvals (17485)
Arizona (168)
Artificial intelligence (62)
Asia (47416)
Australia (8140)
Bankruptcy (389)
Best Places to Work (12150)
Biosimilars (62)
C2C Services and Suppliers (92306)
California (845)
Canada (650)
Cancer (211)
Career advice (3165)
CAR-T (45)
Cell therapy (83)
China (52)
Clinical research (68586)
Collaboration (67)
Colorado (37)
COVID-19 (2717)
Cystic fibrosis (74)
Diabetes (38)
Diagnostics (6404)
Diversity, equity & inclusion (48)
Drug pricing (64)
Earnings (90201)
Employer resources (160)
Europe (106970)
Events (123074)
FDA (17595)
Florida (107)
Funding (42)
Gene therapy (64)
GLP-1 (564)
Government (4950)
Healthcare (20541)
Hotbed/Location (526432)
Idaho (61)
Illinois (238)
Indiana (110)
Infectious disease (2732)
Inflammatory bowel disease (94)
Interviews (733)
IPO (17307)
Job creations (4964)
Job search strategy (2612)
Kansas (95)
Layoffs (441)
Legal (9811)
Liver cancer (57)
Lung cancer (48)
Maine (52)
Management (59)
Manufacturing (58)
Maryland (271)
Massachusetts (467)
Medical device (14145)
Medtech (14148)
Mergers & acquisitions (21480)
Metabolic disorders (194)
Neuroscience (1284)
New Jersey (64)
New York (85)
NextGen Class of 2024 (7592)
Non-profit (5033)
North Carolina (181)
Obesity (125)
Opinion (221)
Patents (38)
Peanut (37)
Pennsylvania (56)
People (62288)
Phase I (21087)
Phase II (29901)
Phase III (22632)
Podcasts (64)
Policy (41)
Postmarket research (3258)
Preclinical (9391)
Rare diseases (96)
Real estate (7133)
Recruiting (72)
Regulatory (24693)
Reports (42)
Research institute (2623)
Resumes & cover letters (582)
South America (1562)
Startups (4164)
Texas (91)
United States (3199)
Vaccines (496)
Washington State (117)
Weight loss (128)
Date
Today (47)
Last 7 days (525)
Last 30 days (2028)
Last 365 days (41170)
2024 (23462)
2023 (42565)
2022 (53928)
2021 (58725)
2020 (57670)
2019 (51320)
2018 (39100)
2017 (36859)
2016 (37803)
2015 (43831)
2014 (38601)
2013 (34722)
2012 (36582)
2011 (36633)
2010 (36209)
794,243 Results for "shionogi and co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.
May 10, 2024
·
6 min read
Business
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
Akili, Inc. including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. (“Shionogi”), a leading global pharmaceutical company.
April 30, 2024
·
9 min read
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
Shionogi & Co., Ltd. announced the company is responding to the urgent global need for additional antimicrobial research and development by establishing its first discovery laboratory in the U.S., in San Diego, California.
June 3, 2024
·
9 min read
Business
Shionogi Strengthens Regulatory Leadership with the Appointment of Dr. Ramón Polo as Senior Vice President, Head of Regulatory Affairs
Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.
February 5, 2024
·
4 min read
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.
July 1, 2024
·
5 min read
Drug Development
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare.
February 27, 2024
·
10 min read
Drug Development
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled Phase 2/3 study (SCORPIO-SR) in patients with mild to moderate COVID-19 in Japan, South Korea and Vietnam in JAMA Network Open.
February 9, 2024
·
11 min read
BioMidwest
AriBio Co., Ltd. Announces Strategic Collaboration with Kentucky Clinical Trial Laboratory (KCTL) to Expand Alzheimer’s Disease Testing
AriBio Co., Ltd. announces the expansion of testing for Alzheimer’s disease by entering into a strategic collaboration with Kentucky Clinical Trial Laboratory for the testing of cerebral spinal fluid to accurately and efficiently aid in the diagnosis of Alzheimer’s disease using the Lumipulse® system from FujireBio.
June 21, 2024
·
3 min read
Drug Development
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.
May 28, 2024
·
2 min read
Business
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan.
February 26, 2024
·
7 min read
1 of 79,425
Next